![]() |
市場調查報告書
商品編碼
1289639
3D蛋白質結構分析市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測,按組件、技術、終端用戶、公司和地區分類3D Protein Structure Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technique, By End User, By company and By Region |
全球3D蛋白質結構分析市場預計將在2023-2027年預測期內出現令人印象深刻的成長。主要因素包括越來越關注X射線晶體學工作流程的自動化和小型化,採用先進技術,以及研發活動的增加,這些都促進了市場的成長。蛋白質結構基本上是一個氨基酸中原子的3D排列。蛋白質的3D結構可以通過大型蛋白質的結晶,然後通過X射線衍射來確定。蛋白質的功能與該蛋白質的結構直接相關。支持市場成長的其他因素有:對蛋白質治療的需求上升,慢性病、傳染病和蛋白質缺乏症的發病率上升,研究實驗室的數量增加,對個性化藥物的高需求,以及政府撥款的增加。另外,用於藥物發現和開發的研究與開發(R&D)支出的上升也促進了市場的成長。
X射線晶體學是一種技術,通過X射線衍射可以獲得蛋白質的3D結構,這有助於了解蛋白質的功能。對現有晶體學的自動化和小型化的日益重視,增強了市場的成長。 X射線晶體學的這種自動化和小型化在3D蛋白質結構分析中更加有效和高效,對工作流程產生了積極的影響。例如,LBNL的生物儀器團隊與ALS、GNF的研究員和Syrrx合作,開發了第一代自動晶體識別和對準系統,打算在同步輻射光束線上工作。
在過去的幾年裡,藥物發現和開發方面的研發活動不斷增加,促進了市場的成長。這要歸功於慢性、蛋白質缺乏的疾病和傳染病的發病率上升。例如,從2010年到2019年,美國食品和藥物管理局(FDA)平均批准了38種新藥,比前十年的平均數多60%。蛋白質分析是識別潛在候選藥物的一個關鍵階段。另外,研發支出的後續成長也在推動全球市場的成長。根據Evaluate Pharma的報告,2012年全球醫藥研發支出為1360億美元,到2019年將增至1860億美元。
蛋白質結構分析設備技術發展的上升正在推動市場的成長。對蛋白質結構的高解析度資訊的需求不斷成長,推動了市場的成長。無X射線電子雷射器、D8 DISCOVER Plus X射線衍射(XRD)等先進技術的出現,由於提高了分析蛋白質3D結構的準確性和速度,對分析有幫助。例如,在2019年,安進公司(美國)和華盛頓大學的蛋白質設計研究所(IPD)合作,測試新技術,並產生可用於尋求新藥物的蛋白質構建策略。
有了給定的市場數據,TechSci Research根據公司的具體需要提供定製服務。該報告有以下定製選項:
The global 3D protein structure analysis market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include a growing focus on automation and miniaturization in X-ray crystallography workflow, adoption of advanced technology, and rise in R&D activities that are augmenting the growth of the market. Protein structure is basically the three-dimensional arrangement of atoms in an amino acid. The three-dimensional structure of a protein at atomic resolution can be determined by crystallizing large proteins and then studying them by x-ray diffraction. Protein function is directly associated with the structure of that protein. The other factors supporting the market's growth are the rising demand for protein therapeutics, the rising prevalence of chronic, infectious, and protein-deficient diseases, the increase in the number of research laboratories, the high demand for personalized medicines, and increasing government grants. Also, the rising research and development (R&D) expenditure for drug discovery and development is facilitating the growth of the market.
X-Ray crystallography is a technique by which the 3D structure of a protein can be obtained by X-ray diffraction, which helps to know the functionality of the protein. Growing emphasis on automation and miniaturization of existing crystallography is augmenting the growth of the market. This automation and miniaturization of x-ray crystallography are positively influencing the workflow by being more effective and efficient in 3D protein structure analysis. For instance, the bio instrumentation team at LBNL collaborated with ALS, GNF's researcher, and Syrrx to develop a first-generation automated crystal recognition and alignment system intended to work at synchrotron beamlines.
Over the past few years, rising R&D activities in drug discovery and development is bolstering the growth of the market. This is attributed to the rising incidences of chronic, protein-deficient diseases and infectious diseases. For instance, the Food and Drug Administration (FDA) approved an average of 38 new drugs from 2010 to 2019, which is 60% more than the prior decade's average. Protein analysis is a crucial phase in identifying potential candidates. Also, the subsequent rise in R&D expenditure is propelling the growth of the market globally. As per the Evaluate Pharma report, pharmaceutical R&D expenditure globally was valued at USD 136 billion in 2012, which raised to USD 186 billion in 2019.
The rise in technological developments in equipment for protein structure analysis is fueling the growth of the market. The growing need for high-resolution information on protein structures is driving the growth of the market. The advent of advanced technologies like X-ray-free electron lasers, D8 DISCOVER Plus X-ray Diffraction (XRD), and others are helpful due to the enhanced accuracy and speed in analyzing the 3D structure of the protein. For instance, in 2019, Amgen (US) and the University of Washington's Institute for Protein Design (IPD) collaborated to test new technologies and generate protein-building tactics that can be applied to seek new drugs.
The global 3D protein structure analysis market is segmented into components, techniques, end users, and company. Based on components, the market is divided into instruments, consumables, and software. Based on technique, the market is divided into x-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, cryo-electron microscopy (Cryo-EM), and small angle x-ray scattering (SAXS). Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of chronic and infectious diseases in the country.
Bruker Corporation, JEOL Ltd., Spectris plc, Thermo Fisher Scientific Inc., Merck KGaA, Schrodinger, Inc., Cambridge Isotope Laboratories, Inc., Rigaku Corporation, Jena Bioscience GmbH, and Dassault Systemes SE are some of the leading companies operating in the market.
In this report, global 3D protein structure analysis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global 3D Protein Structure Analysis Market
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: